Nicholas R Lenze1, Douglas R Farquhar2, Siddharth Sheth3, Jose P Zevallos4, Catherine Lumley2, Jeffrey Blumberg2, Samip Patel2, Trevor Hackman2, Mark C Weissler2, Wendell G Yarbrough5, Andrew F Olshan6, Adam M Zanation2. 1. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, United States. Electronic address: nlenzemed@gmail.com. 2. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, United States. 3. Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, United States. 4. Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, United States. 5. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, NC, United States. 6. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Abstract
OBJECTIVE: To estimate the relative prognostic ability of socioeconomic status (SES) compared to overall stage for HPV-negative head and neck squamous cell carcinoma (HNSCC) MATERIALS AND METHODS: Data were obtained from the Carolina Head and Neck Cancer Epidemiology Study (CHANCE). An empirical 4-category SES classification system was created. Cox proportional hazards models, survival gradients, Bayesian information criterion (BIC), and Harrell's C index were used to estimate the prognostic ability of SES compared to stage on overall survival (OS). RESULTS: The sample consisted of 1229 patients with HPV-negative HNSCC. Patients with low SES had significantly increased risk of mortality at 5 years compared to patients with high SES (HR 3.11, 95% CI 2.07-4.67; p < 0.001), and the magnitude of effect was similar to overall stage (HR 3.01, 95% CI 2.35-3.86; p < 0.001 for stage IV versus I). Compared to overall stage, the SES classification system had a larger total survival gradient (35.8% vs. 29.1%), similar model fit (BIC statistic of 7412 and 7388, respectively), and similar model discriminatory ability (Harrell's C index of 0.61 and 0.64, respectively). The association between low SES and OS persisted after adjusting for age, sex, race, alcohol, smoking, overall stage, tumor site, and treatment in a multivariable model (HR 2.96, 95% CI 1.92-4.56; p < 0.001). CONCLUSION: SES may have a similar prognostic ability to overall stage for patients with HPV-negative HNSCC. Future research is warranted to validate these findings and identify evidence-based interventions for addressing barriers to care for patients with HNSCC.
OBJECTIVE: To estimate the relative prognostic ability of socioeconomic status (SES) compared to overall stage for HPV-negative head and neck squamous cell carcinoma (HNSCC) MATERIALS AND METHODS: Data were obtained from the Carolina Head and Neck Cancer Epidemiology Study (CHANCE). An empirical 4-category SES classification system was created. Cox proportional hazards models, survival gradients, Bayesian information criterion (BIC), and Harrell's C index were used to estimate the prognostic ability of SES compared to stage on overall survival (OS). RESULTS: The sample consisted of 1229 patients with HPV-negative HNSCC. Patients with low SES had significantly increased risk of mortality at 5 years compared to patients with high SES (HR 3.11, 95% CI 2.07-4.67; p < 0.001), and the magnitude of effect was similar to overall stage (HR 3.01, 95% CI 2.35-3.86; p < 0.001 for stage IV versus I). Compared to overall stage, the SES classification system had a larger total survival gradient (35.8% vs. 29.1%), similar model fit (BIC statistic of 7412 and 7388, respectively), and similar model discriminatory ability (Harrell's C index of 0.61 and 0.64, respectively). The association between low SES and OS persisted after adjusting for age, sex, race, alcohol, smoking, overall stage, tumor site, and treatment in a multivariable model (HR 2.96, 95% CI 1.92-4.56; p < 0.001). CONCLUSION: SES may have a similar prognostic ability to overall stage for patients with HPV-negative HNSCC. Future research is warranted to validate these findings and identify evidence-based interventions for addressing barriers to care for patients with HNSCC.
Authors: David W Baker; Julie A Gazmararian; Mark V Williams; Tracy Scott; Ruth M Parker; Diane Green; Junling Ren; Jennifer Peel Journal: Am J Public Health Date: 2002-08 Impact factor: 9.308
Authors: Douglas R Farquhar; Kimon Divaris; Angela L Mazul; Mark C Weissler; Jose P Zevallos; Andrew F Olshan Journal: Oral Oncol Date: 2017-10 Impact factor: 5.337
Authors: Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: K P Chu; S Habbous; Q Kuang; K Boyd; M Mirshams; F-F Liu; O Espin-Garcia; W Xu; D Goldstein; J Waldron; B O'Sullivan; S H Huang; G Liu Journal: Cancer Epidemiol Date: 2015-12-17 Impact factor: 2.984
Authors: Kimon Divaris; Andrew F Olshan; Joanna Smith; Mary E Bell; Mark C Weissler; William K Funkhouser; Patrick T Bradshaw Journal: Cancer Causes Control Date: 2010-01-05 Impact factor: 2.506
Authors: Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-03-01 Impact factor: 6.223